All entries for: Merck

November 3, 2023

Merck

Negative Outlook

Rahway, NJ
50,001+ employees

“Pursuant to the IRA’s Program, discussions with the government will occur in 2023 and 2024, with government price-setting becoming effective on January 1, 2026. The Company has sued the U.S. government regarding the IRA’s Program (see Note 10 to the condensed consolidated financial statements). Furthermore, the Biden Administration and
– 31 –

Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company anticipates all of these actions and additional actions in the future will negatively affect sales and profits.”

Disease Area: Oncology
Drug Type: Biologic, Small Molecule
August 7, 2023

Merck

Negative Outlook

Rahway, NJ
50,001+ employees
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
May 5, 2023

Merck

Negative Outlook

Rahway, NJ
50,001+ employees
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
November 3, 2022

Merck

Negative Outlook

Rahway, NJ
50,001+ employees

• IRA & 9-Month Period in 2022: “…the Company’s sales performance in the first nine months of 2022 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In the U.S., Congress recently passed the Inflation Reduction Act, which makes significant changes to how drugs are covered and paid for under the Medicare” • General Impact: “The Company anticipates all of these actions and additional actions in the future will negatively affect sales and profits”

Disease Area: Oncology
Drug Type: Biologic, Small Molecule
Scroll to Top